Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Larsson, Anna ^a   Fridberg, Marie ^a   Gaber, Alexander ^a   Nodin, Björn ^a   Levéen, Per ^a   Jönsson, Göran ^a   Uhlén, Mathias ^b   Birgisson, Helgi ^c   Jirström, Karin ^a  

^a LUND UNIVERSITY   (Sweden)

^b ALBANOVA UNIVERSITY CENTER   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PODOCALYXIN; PODOCALYXIN LIKE 1 PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; TISSUE LEVEL; TISSUE MICROARRAY; VALIDATION PROCESS;

AGED; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SIALOGLYCOPROTEINS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84863455288     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-282     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
2. Murphy JE, Ryan DP. American Society of Clinical Oncology 2010 colorectal update. Expert Rev Anticancer Ther 2010, 10(9):1371-1373. 10.1586/era.10.123, 20836671.
3. O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011, 29(25):3381-3388. 10.1200/JCO.2010.34.3426, 3164243, 21788561.
4. McNagny KM, Pettersson I, Rossi F, Flamme I, Shevchenko A, Mann M, Graf T. Thrombomucin, a novel cell surface protein that defines thrombocytes and multipotent hematopoietic progenitors. The Journal of cell biology 1997, 138(6):1395-1407. 10.1083/jcb.138.6.1395, 2132552, 9298993.
5. Horvat R, Hovorka A, Dekan G, Poczewski H, Kerjaschki D. Endothelial cell membranes contain podocalyxin-the major sialoprotein of visceral glomerular epithelial cells. The Journal of cell biology 1986, 102(2):484-491. 10.1083/jcb.102.2.484, 2114082, 3511072.
6. Takeda T, Go WY, Orlando RA, Farquhar MG. Expression of podocalyxin inhibits cell-cell adhesion and modifies junctional properties in Madin-Darby canine kidney cells. Mol Biol Cell 2000, 11(9):3219-3232. 14987, 10982412.
7. Kavoura E, Gakiopoulou H, Paraskevakou H, Marinaki S, Agrogiannis G, Stofas A, Boletis I, Patsouris E, Lazaris AC. Immunohistochemical evaluation of podocalyxin expression in glomerulopathies associated with nephrotic syndrome. Hum Pathol 2011, 42(2):227-235. 10.1016/j.humpath.2010.05.028, 21106221.
8. Somasiri A, Nielsen JS, Makretsov N, McCoy ML, Prentice L, Gilks CB, Chia SK, Gelmon KA, Kershaw DB, Huntsman DG, et al. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res 2004, 64(15):5068-5073. 10.1158/0008-5472.CAN-04-0240, 15289306.
9. Casey G, Neville PJ, Liu X, Plummer SJ, Cicek MS, Krumroy LM, Curran AP, McGreevy MR, Catalona WJ, Klein EA, et al. Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet 2006, 15(5):735-741. 10.1093/hmg/ddi487, 16434482.
10. Hsu YH, Lin WL, Hou YT, Pu YS, Shun CT, Chen CL, Wu YY, Chen JY, Chen TH, Jou TS. Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7. Am J Pathol 2010, 176(6):3050-3061. 10.2353/ajpath.2010.090539, 2877864, 20395446.
11. Nielsen JS, Graves ML, Chelliah S, Vogl AW, Roskelley CD, McNagny KM. The CD34-related molecule podocalyxin is a potent inducer of microvillus formation. PLoS One 2007, 2(2):e237. 10.1371/journal.pone.0000237, 1796660, 17311105.
12. Meng X, Ezzati P, Wilkins JA. Requirement of podocalyxin in TGF-beta induced epithelial mesenchymal transition. PLoS One 2011, 6(4):e18715. 10.1371/journal.pone.0018715, 3075272, 21533279.
13. Cipollone JA, Graves ML, Kobel M, Kalloger SE, Poon T, Gilks CB, McNagny KM, Roskelley CD. The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. Clinical & experimental metastasis 2012, 29(3):239-252. 10.1007/s10585-011-9446-0, 23077723.
14. Cheung HH, Davis AJ, Lee TL, Pang AL, Nagrani S, Rennert OM, Chan WY. Methylation of an intronic region regulates miR-199a in testicular tumor malignancy. Oncogene 2011, 30(31):3404-3415. 10.1038/onc.2011.60, 3117973, 21383689.
15. Larsson A, Johansson ME, Wangefjord S, Gaber A, Nodin B, Kucharzewska P, Welinder C, Belting M, Eberhard J, Johnsson A, et al. Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer 2011, 105(5):666-672. 10.1038/bjc.2011.295, 3188928, 21829192.
16. Wallin U, Glimelius B, Jirstrom K, Darmanis S, Nong RY, Ponten F, Johansson C, Pahlman L, Birgisson H. Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. Br J Cancer 2011, 104(10):1619-1627. 10.1038/bjc.2011.112, 3101900, 21468045.
17. Gaber A, Johansson M, Stenman UH, Hotakainen K, Ponten F, Glimelius B, Bjartell A, Jirstrom K, Birgisson H. High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Br J Cancer 2009, 100(10):1540-1548. 10.1038/sj.bjc.6605047, 2696764, 19384300.
18. Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ, Pahlman L, Sobrero A, Douillard JY. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007, 99(13):998-1003. 10.1093/jnci/djm024, 17596575.
19. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature medicine 1998, 4(7):844-847. 10.1038/nm0798-844, 9662379.
20. Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Molecular & cellular proteomics: MCP 2005, 4(12):1920-1932. 10.1074/mcp.M500279-MCP200, 23077755.
21. Ponten F, Jirstrom K, Uhlen M. The Human Protein Atlas-a tool for pathology. J Pathol 2008, 216(4):387-393. 10.1002/path.2440, 18853439.
22. Rubie C, Kempf K, Hans J, Su T, Tilton B, Georg T, Brittner B, Ludwig B, Schilling M. Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. Mol Cell Probes 2005, 19(2):101-109. 10.1016/j.mcp.2004.10.001, 15680211.
23. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007, 50(1):151-162. 10.1111/j.1365-2559.2006.02551.x, 17204028.
24. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor " budding" in patients with colorectal cancer. Dis Colon Rectum 1993, 36(7):627-635. 10.1007/BF02238588, 8348847.
25. Horvat R, Hovorka A, Dekan G, Poczewski H, Kerjaschki D. Endothelial cell membranes contain podocalyxin-the major sialoprotein of visceral glomerular epithelial cells. J Cell Biol 1986, 102(2):484-491. 10.1083/jcb.102.2.484, 2114082, 3511072.
26. Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, Yi EC, Dai H, Thorsson V, Eng J, et al. Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics 2004, 3(10):960-969. 10.1074/mcp.M400055-MCP200, 15238602.
27. Nie L, Wu G, Zhang W. Correlation between mRNA and protein abundance in Desulfovibrio vulgaris: a multiple regression to identify sources of variations. Biochem Biophys Res Commun 2006, 339(2):603-610. 10.1016/j.bbrc.2005.11.055, 16310166.
28. Schlemmer BO, Sorensen BS, Overgaard J, Olsen KE, Gjerdrum LM, Nexo E. Quantitative PCR-new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization. Scand J Clin Lab Invest 2004, 64(5):511-522. 10.1080/00365510410002922, 15276916.
29. Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002, 1(4):304-313. 10.1074/mcp.M200008-MCP200, 12096112.
30. Lichtinghagen R, Musholt PB, Lein M, Romer A, Rudolph B, Kristiansen G, Hauptmann S, Schnorr D, Loening SA, Jung K. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol 2002, 42(4):398-406. 10.1016/S0302-2838(02)00324-X, 12361907.